S-1/temozolomide versus S-1/temozolomide plus thalidomide in advanced pancreatic and non-pancreatic neuroendocrine tumours (STEM): A randomised, open-label, multicentre phase 2 trial
-
Published:2022-12
Issue:
Volume:54
Page:101667
-
ISSN:2589-5370
-
Container-title:eClinicalMedicine
-
language:en
-
Short-container-title:eClinicalMedicine
Author:
Chi Yihebali, Song Lijie, Liu Weili, Zhou Yuhong, Miao Yadong, Fang Weijia, Tan Huangying, Shi Susheng, Jiang Hai, Xu Jianming, Jia Ru, Zheng Bo, Jiang Liming, Zhao Jiuda, Zhang Rui, Tan Huijing, Wang Yuehua, Chen Qichen, Yang Minjie, Guo Xi, Tong Zhou, Qi Zhirong, Zhao Fuxing, Yan Xiaofei, Zhao HongORCID
Reference34 articles.
1. Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin;Basu;Endocr Relat Cancer,2010 2. Role of somatostatins in gastroenteropancreatic neuroendocrine tumour development and therapy;Oberg;Gastroenterology,2010 3. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine tumours in the United States;Dasari;JAMA Oncol,2017 4. A tale of two tumours: treating pancreatic and extrapancreatic neuroendocrine tumours;Halperin;Annu Rev Med,2015 5. Placebo-controlled, double-blind, prospective, randomised study on the effect of octreotide LAR in the control of tumour growth in patients with metastatic neuroendocrine midgut tumours: a report from the PROMID Study Group;Rinke;J Clin Oncol,2009
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|